Math-free guides for glycerin and allergens at variable subcutaneous injection volumes: How’s my dosing? Update.

Related Articles

Math-free guides for glycerin and allergens at variable subcutaneous injection volumes: How’s my dosing? Update.

Ann Allergy Asthma Immunol. 2016 Mar 24;

Authors: Grier TJ, Converse LM, Rekkerth DJ, Renahan KE

Abstract
BACKGROUND: Current summaries of effective maintenance dose ranges for subcutaneous immunotherapy (SCIT) are based on administration of 0.5-mL volumes. Extract formulations delivering equivalent dose ranges for practices using different injection volumes have not been reported, and calculation of the final glycerin concentrations in these solutions remains an inconvenient and repetitive process.
OBJECTIVES: To create math-free guides for allergen doses and glycerin concentrations that identify the extract concentrate volumes required to deliver doses within the ranges cited in the 2011 immunotherapy practice parameters for clinicians using 5.0-mL maintenance vials and injection volumes ranging from 0.2 to 1.0 mL.
METHODS: Algebraic calculations were performed to determine the specific combinations of extract concentrate strengths, volumes of these products in patient vaccines, and injection volumes needed for administration of target allergen doses spanning the current SCIT practice parameter recommendations.
RESULTS: For each product or group (nonstandardized extracts), tables were constructed to define the allergen doses provided by various combinations of extract concentrate volumes and injection volumes. The values within the effective dose ranges for each product were highlighted to facilitate comparisons of specific conditions relevant to allergy specialists. Glycerin tables were also created to permit convenient assessments of the final concentrations of this stabilizer in patient prescriptions.
CONCLUSIONS: SCIT dosing and glycerin tables are useful tools to assist allergists with practice decisions that involve variable patient formulas and injection volumes and can help identify suitable conditions for treatment of patients presenting with diverse allergen sensitivities and specificity profiles.

PMID: 27017565 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Shawnee Mission Health Update: What’s going around? Asthma – Prairie Village Post


Prairie Village Post

Shawnee Mission Health Update: What's going around? Asthma
Prairie Village Post
This time of year we are seeing a lot of colds and flus, and anytime that happens you know we're going to see some asthma outbreaks. If you have a history of asthma, treatment always starts with prevention. Be sure to get your flu shot, be sure to get

View full post on asthma – Google News

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults – Reuters


MedPage Today

UPDATE 1-FDA panel backs approval of GSK asthma drug in adults
Reuters
If approved, the drug would be marketed under the trade name Nucala and be the first new biologic treatment for severe asthma in more than a decade. Asthma affects more than 22 million people in the United States. Severe asthma accounts for 5 to 10 …
UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in StreetInsider.com
Asthma Drug Targeting IL-5 Wins Partial Backing From FDA AdvisersMedPage Today
FDA committee recommends approval of Nucala for adults with severe asthmaHealio
Reuters India
all 12 news articles »

View full post on asthma – Google News

UPDATE: Glaxo’s (GSK) Severe Asthma Drug Mepolizumab Found Effective in … – StreetInsider.com

UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in
StreetInsider.com
GlaxoSmithKline (NYSE: GSK) severe asthma drug, mepolizumab, is effective in adults, FDA panel says, according to Bloomberg. UPDATE – Last November, Glaxo announced that it filed regulatory submissions in the USA and Europe for mepolizumab for …

View full post on asthma – Google News

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents – Reuters


Channel News Asia

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters
The panel voted 16-4 that Breo Ellipta should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19-1 that the data did not support approval for use in children aged 12 to 17. The FDA is not obliged to follow the
U.S. Panel Backs Glaxo's Breo for Adults With Asthma, Not KidsBloomberg
GSK's Breo for asthma? FDA panel says yes–but only in adultsFiercePharma
FDA panel backs Glaxo asthma drug for adults, not adolescentsBusiness Insider
WallStreet.org –Fox Business
all 26 news articles »

View full post on asthma – Google News

[Very preterm births in French Polynesia: Update and proposal for follow-up.]

[Very preterm births in French Polynesia: Update and proposal for follow-up.]

Arch Pediatr. 2014 Dec 29;

Authors: Besnard M, Kuo P, Pawlotsky F, Guyot D, Elie V, Papouin-Rauzy M

Abstract
INTRODUCTION: The care of premature infants in French Polynesia is complicated by this country’s geographic isolation. We undertook an evaluation of the medical care of very premature infants (VPIs) to find local solutions to this problem.
OBJECTIVES: The objectives were to determine the incidence, mortality, and the short- and long-term outcome of very preterm infants in French Polynesia.
METHODS: We retrospectively reviewed the medical charts of all infants born alive at<32 gestational age (GA) and>24 GA from January 2007 to December 2011. Perinatal characteristics and outcomes were examined by univariate and multivariate analysis.
RESULTS: In total, 204 VPIs were born during the 5-year study period, comprising 0.9% of all births. Infants less than 28 GA comprised 0.1% of all births. Sixty-two percent of mothers were of extreme age including 43% less than 25 years old. Prematurity was attributed to spontaneous preterm labor in 63% of cases and preeclampsia in 29%. Spontaneous multiple pregnancies comprised 15% of the cases. Alcohol and tobacco consumption were frequently noted (>8% and 26% mothers, respectively). Seventy-eight percent of VPIs had received prenatal steroids. Intrauterine growth was normal in 89%. Mortality occurred in 9.3% (19 patients). Mortality was higher with lower gestational age (P<0.05) and absence of prenatal steroids (P<0.05) in univariate and multivariate analysis. The primary cause of death was sepsis. Hyaline membrane disease occurred in 44% of patients, 80% of whom received surfactant therapy. In total, 16.2% newborns developed bronchodysplasia, 3.4% necrotizing enterocolitis, 3% cerebral hemorrhage, and 1.5% leukomalacia. Long-term outcome was marked by 52% of the patients lost to follow-up by 2 years of age, mostly because of geographic isolation. For the 72 patients followed-up, four developed asthma and three cerebral palsy; 70% were attending school by 3 years of age.
CONCLUSIONS: The incidence, mortality, and morbidity of very preterm birth in French Polynesia are comparable to reports from metropolitan centers in France. Conversely, nearly one-half of the patients were lost to follow-up, precluding meaningful information on intellectual development and other outcomes. We recommend organizing a long-term follow-up network to detect cognitive sequelae and adapting such a system to the geographical residence of French Polynesian families.

PMID: 25554672 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

AB Science: Web conference on masitinib in asthma – Safety and Efficacy Update – GlobeNewswire (press release)

AB Science: Web conference on masitinib in asthma – Safety and Efficacy Update
GlobeNewswire (press release)
Paris, France, Nov. 25, 2014 (GLOBE NEWSWIRE) — AB Science SA (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web …

and more »

View full post on asthma – Google News

UPDATE 1-FDA says asthma drug Xolair raises risk of heart, brain problems – Reuters


GlobalPost

UPDATE 1-FDA says asthma drug Xolair raises risk of heart, brain problems
Reuters
Xolair is an injectible drug that was originally approved in 2003 to treat moderate to severe asthma in adults and children aged 12 or over whose condition was not controlled by inhaled steroids. The drug is also approved to treat chronic idiopathic
FDA says asthma drug Xolair raises risk of heart, brain problemsYahoo News
FDA warns of increased risks of asthma drug XolairAAP News (subscription)
FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular EventsMonthly Prescribing Reference

all 19 news articles »

View full post on asthma – Google News